Quarterly Results of Operations (Unaudited) (Tables)

12 Months Ended

Jan. 29, 2022

Quarterly Financial Information Disclosure [Abstract]


	Net Sales		Gross Margin		Net Income (Loss)		Net Income (Loss) Per Common Share - Basic		Net Income (Loss) Common and Common Equivalent Share - Diluted

	(dollars in thousands, except per share amounts)
Fiscal year ended January 29, 2022:
First quarter	$	387,961	$	126,795	$	(8,929)	$	(0.08)	$	(0.08)
Second quarter	472,059		181,458		26,187		0.22		0.21
Third quarter (2)	453,644		184,439		18,226		0.15		0.15
Fourth quarter	496,263		171,307		10,734		0.09		0.09
Fiscal year ended January 30, 2021:
First quarter (3)	$	280,264	$	(11,095)	$	(178,290)	$	(1.55)	$	(1.55)
Second quarter (4)	306,174		44,766		(46,845)		(0.40)		(0.40)
Third quarter (5)	351,416		77,164		(55,868)		(0.48)		(0.48)
Fourth quarter (6)	386,197		73,338		(79,141)		(0.68)		(0.68)

(1) The sum of the quarters may not equal the corresponding year-to-date amount due to rounding.

(2) Results for the third quarter of fiscal 2021 include litigation settlement charges of $4 million, after-tax.

(3) Results for the first quarter of fiscal 2020 include the following after-tax charges as a result of the impact of the pandemic: inventory write-offs of $26.1 million; long-lived asset store impairment of $13.9 million; right of use store asset impairment of $1.8 million; goodwill impairment charges of $68.4 million; and impairments on indefinite-lived intangible assets of $24.6 million.

(4) Results for the second quarter of fiscal 2020 include inventory write-offs of $8.0 million, after-tax, as a result of the impact of the pandemic.

(5) Results for the third quarter of fiscal 2020 include other long-lived impairment charges of $6.3 million, after-tax, as a result of the impact of the pandemic.

(6) Results for the fourth quarter of fiscal 2020 include the following significant non-cash charges as a result of the impact of the pandemic: long-lived asset store impairment of $1.8 million, after-tax; impairment on other right of use assets of $1.2 million, after-tax; impairments on indefinite-lived intangible assets of $0.9 million, after-tax; and a deferred tax asset valuation allowance of $32.1 million within the Company's income tax provision (benefit).